Author: Pradip Tikhe

An under-the-radar biotech firm called Tempest Therapeutics Inc. notched its best week on record after results from a liver cancer trial sent the stock surging 3,973% — and tumbling the next day. Wall Street cheered as the stock shot up to $9.77 on Wednesday when the drug developer said its experimental cancer therapy in a cocktail with two Roche Holding AG drugs worked better than the pair of drugs by themselves. The surge after the Roche-run study helped push Tempest’s market value to $130 million from a mere $3 million as of the previous day’s close. Shares of Tempest have…

Read More

As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall health of the planet that is only our home. This technology is being developed with the aim to reduce rates of infectious diseases, save lives, lower the odds of life-threatening diseases affecting the world’s population, customize patient treatments to increase the odds of success and lower the odds of side-effects as well as to create precise tools for early disease detection. Such a tool has been developed by a molecular…

Read More

Sana Biotechnology is restructuring and narrowing its focus for the second time in less than a year. With its stock in the doldrums, the cell engineering biotech is pulling back from its in vivo delivery platform and reducing its head count by 29% to stretch its cash runway deeper into 2025. Seattle-based Sana went public just as the biotech stock market peaked in February 2021, enabling it to raise $587.5 million before entering the clinic. The stock has followed the broader market down ever since, sliding from its early peak of almost $40 per share to below $4 today. Plans…

Read More

Jane Grogan, Ph.D., is just a week into her new job leading Biogen’s research unit, but she’s chomping at the bit to apply the fast-paced rigor of the biotech world to her new employer’s pipeline. The ex-chief scientific officer of ArsenalBio and Graphite Bio officially started as the head of research at Biogen Oct. 2, with much of her first days spent acclimating to the team and getting a grasp on the existing projects. But as the company continues to follow through with a large-scale reorganization that includes laying off around 1,000 employees, quickly realigning scientists’ focus is a pressing matter.  “The opportunity as…

Read More

s the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall health of the planet that is only our home. This technology is being developed with the aim to reduce rates of infectious diseases, save lives, lower the odds of life-threatening diseases affecting the world’s population, customize patient treatments to increase the odds of success and lower the odds of side-effects as well as to create precise tools for early disease detection. Such a tool has been developed by a molecular genetics…

Read More

VitaDAO is announcing the launch of Matrix Biosciences, a biotechnology company led by University of Rochester anti-aging researcher Vera Gorbunova. The launch comes with $300,000 in initial financing, with more funding to come in early 2024. The company will expand on Gorbunova’s research on the long life spans and cancer resistance of naked mole rats and examine whether a compound found in the rats could improve human lifespan. Launched in 2021, VitaDAO funds “longevity” research aimed at extending human life. The DAO currently funds 20 projects, primarily focused on potential “moonshot” contributions to longevity science. Todd White, a VitaDAO core…

Read More

Atsena Therapeutics has cut staff to funnel more money toward an inherited retinal disease program that just began dosing for a phase 1/2 trial in August. The company confirmed the layoffs in a statement to Fierce Biotech Thursday, saying the reduction in force happened to “prioritize resources” toward ATSN-201, a gene therapy for X-linked retinoschisis. The disease is an inherited retinal condition that causes early vision loss in about 30,000 males in the U.S. and Europe. Atsena declined to say how many employees were impacted, but a LinkedIn profile lists 42 employees total. The program is the first to use Atsena’s new…

Read More

Damian here with the precarious case of gene therapy in Europe, a long-awaited coup for Novavax, and the unwinding of Amgen’s success story. The need-to-know this morning• Sanofi will spend up to $1.5 billion to co-develop and co-commercialize Teva’s experimental arthritis drug as a treatment for inflammatory bowel disease.• Eli Lilly announced a reshuffling of its leadership, including promoting David Hyman to chief medical officer. Does gene therapy have a future in Europe?For Stella Pelteki, who has lived with a blood disorder since birth, the 2019 European approval of a gene therapy for her disease had life-changing potential. But within months, that promise came…

Read More

the place where people of all backgrounds come with hopes and dreams of making a better life for themselves – is just recently becoming a life sciences powerhouse, attracting many biotech companies, after a $1 billion public investment in the industry from the City of New York. This initiative, called LifeSci NYC, will invest $450 million to spur new research, $600 million to construct new labs and incubator spaces, and $20 million to build a pipeline of diverse talent. In doing so, the initiative aims to create 40,000 jobs, unlock 10 million square feet of wet- and dry-lab space, and spur the…

Read More

The city doesn’t have the legacy of a biotech giant like Boston or San Francisco. It doesn’t crack the top 13 life sciences markets, which includes neighboring Houston, according to PitchBook. It’s in a conservative state that the Biden Administration would seemingly want to avoid. But Dallas, along with a coalition of Texas’ biggest cities, lobbied for the biotech research agency’s headquarters for more than two years in private meetings and public declarations, ignoring any concerns from outsiders about the region’s chances. Everything’s bigger in Texas, including confidence, and on a relatively subdued Zoom call Tuesday, the state’s diligence paid off ten-fold. ARPA-H will…

Read More